Novo Nordisk Transfers Parkinson’s Cell Therapy Project to AI-Driven Cellular Intelligence

Novo Nordisk is taking an equity stake in Cellular Intelligence and stands to receive future milestone payments and royalties. Cellular Intelligence intends to apply its AI technology to STEM-PD, a stem-cell-derived Parkinson’s treatment that Novo discontinued in October last year. The transfer marks a strategic move to advance the therapy using AI innovation in biotech.